1. Home
  2. EXEL
  3. EXEL News

Latest Exelixis Inc. (EXEL) News on March 26, 2025

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally
EXEL

Investor's Business Daily

2 days ago

Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?
EXEL

Zacks

5 days ago

Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

6 days ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Exelixis Growth Continues with Big Money Boosts
EXEL

FX Empire

7 days ago

Exelixis Growth Continues with Big Money Boosts

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires
EXEL

Insider Monkey

8 days ago

Exelixis, Inc. (EXEL): Among the Best Biotech Stocks to Buy According to Billionaires

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?
EXEL

Zacks

13 days ago

Exelixis (EXEL) Up 13.4% Since Last Earnings Report: Can It Continue?

EXEL

MT Newswires

13 days ago

RBC Raises Price Target on Exelixis to $40 From $38, Keeps Outperform Rating

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?
EXEL

Zacks

14 days ago

EXEL vs. ARGX: Which Stock Should Value Investors Buy Now?

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

14 days ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

EXEL

Argus Research

22 days ago

EXEL: Raising target price to $42.00

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
EXEL

Zacks

22 days ago

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

Exploring 3 High Growth Tech Stocks In The US Market
EXEL

Simply Wall St.

22 days ago

Exploring 3 High Growth Tech Stocks In The US Market

Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?
EXEL

Insider Monkey

25 days ago

Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now?

Exelixis focuses on future growth despite COSMIC-313 trial challenges
EXEL

Pharmaceutical Technology

a month ago

Exelixis focuses on future growth despite COSMIC-313 trial challenges

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors
EXEL

Zacks

a month ago

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

EXEL

Argus Research

a month ago

EXEL: Raising target price to $40.00

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
EXEL

Business Wire

a month ago

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March

Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia
EXEL

Investor's Business Daily

a month ago

Analysts Give The Green Light To Two Stocks With Brighter Outlook Than Even Nvidia

EXEL or TECH: Which Is the Better Value Stock Right Now?
EXEL

Zacks

a month ago

EXEL or TECH: Which Is the Better Value Stock Right Now?

EXEL

MT Newswires

a month ago

Wells Fargo Downgrades Exelixis to Equalweight From Overweight, Price Target is $36

Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks
EXEL

Insider Monkey

a month ago

Exelixis, Inc. (EXEL): Among Renaissance Technologies Portfolio’s Top Stock Picks

Why Exelixis Stock Trounced the Market on Thursday
EXEL

Motley Fool

a month ago

Why Exelixis Stock Trounced the Market on Thursday

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
EXEL

Benzinga

a month ago

Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?

Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point
EXEL

Simply Wall St.

a month ago

Exelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting Point

EXEL

MT Newswires

a month ago

Exelixis Board Authorizes Additional Share Buyback Program of Up To $500 Million; Shares Advance After Hours

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
EXEL

Business Wire

a month ago

Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program

Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
EXEL

Zacks

a month ago

Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

a month ago

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

EXEL

MT Newswires

a month ago

Exelixis Insider Sold Shares Worth $1,541,343, According to a Recent SEC Filing

EXEL

Argus Research

a month ago

EXEL: Raising target price to $37.00

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
EXEL

Zacks

a month ago

Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?

International Markets and Exelixis (EXEL): A Deep Dive for Investors
EXEL

Zacks

a month ago

International Markets and Exelixis (EXEL): A Deep Dive for Investors

Five-year results see Exelixis’ RCC therapy extending overall survival
EXEL

Clinical Trials Arena

a month ago

Five-year results see Exelixis’ RCC therapy extending overall survival

Exelixis Full Year 2024 Earnings: EPS Beats Expectations
EXEL

Simply Wall St.

a month ago

Exelixis Full Year 2024 Earnings: EPS Beats Expectations

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
EXEL

Business Wire

a month ago

Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
EXEL

Zacks

a month ago

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
EXEL

Business Wire

a month ago

Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit

EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
EXEL

Zacks

a month ago

EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus

Exelixis Inc (EXEL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
EXEL

GuruFocus.com

a month ago

Exelixis Inc (EXEL) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Exelixis (EXEL) Q4 2024 Earnings Call Transcript
EXEL

Motley Fool

a month ago

Exelixis (EXEL) Q4 2024 Earnings Call Transcript

Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
EXEL

Zacks

a month ago

Exelixis (EXEL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates
EXEL

Zacks

a month ago

Exelixis (EXEL) Q4 Earnings and Revenues Top Estimates

EXEL

MT Newswires

a month ago

Exelixis' Q4 Non-GAAP Earnings, Revenue Rise

EXEL

Associated Press Finance

a month ago

Exelixis: Q4 Earnings Snapshot

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
EXEL

Business Wire

a month ago

Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update

2 Stocks to Buy With Less Than $40
EXEL

Motley Fool

a month ago

2 Stocks to Buy With Less Than $40

The 10 best stocks of the last decade
EXEL

Quartz

2 months ago

The 10 best stocks of the last decade

Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United Airlines
EXEL

Zacks

2 months ago

Zacks.com featured highlights include Pilgrim's Pride, Exelixis, Synchrony and United Airlines

EXEL or TECH: Which Is the Better Value Stock Right Now?
EXEL

Zacks

2 months ago

EXEL or TECH: Which Is the Better Value Stock Right Now?

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
EXEL

Zacks

2 months ago

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics
EXEL

Zacks

2 months ago

Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics

EXEL

Argus Research

2 months ago

EXEL: What does Argus have to say about EXEL?

Exploring High Growth Tech Stocks in February 2025
EXEL

Simply Wall St.

2 months ago

Exploring High Growth Tech Stocks in February 2025

Here's Why Exelixis (EXEL) is a Strong Value Stock
EXEL

Zacks

2 months ago

Here's Why Exelixis (EXEL) is a Strong Value Stock

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?
EXEL

Zacks

2 months ago

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

EXEL

Argus Research

2 months ago

EXEL: Rating increased to a BUY

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
EXEL

Business Wire

2 months ago

Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?
EXEL

Zacks

2 months ago

Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?

Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
EXEL

Zacks

2 months ago

Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform

EXEL

MT Newswires

2 months ago

Truist Lifts Price Target on Exelixis to $43 From $42, Keeps Buy Rating

EXEL

MT Newswires

2 months ago

Morgan Stanley Upgrades Exelixis to Overweight From Equalweight, Raises Price Target to $40 From $30

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
EXEL

Business Wire

2 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025

EXEL

MT Newswires

2 months ago

Exelixis Reports Results on Drug Study to Treat Advanced Gastrointestinal Neuroendocrine Tumors

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
EXEL

Business Wire

2 months ago

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025

Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?
EXEL

GuruFocus.com

2 months ago

Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?

Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns
EXEL

GuruFocus.com

2 months ago

Exelixis Stock Falls as Oppenheimer Downgrades Over Drug Differentiation Concerns

EXEL

MT Newswires

2 months ago

Oppenheimer Downgrades Exelixis to Perform From Outperform, Adjusts Price Target to $33 From $41

Revenues, Treatment Pipeline Driving Exelixis Higher
EXEL

FX Empire

2 months ago

Revenues, Treatment Pipeline Driving Exelixis Higher

EXEL

Argus Research

2 months ago

EXEL: Raising target price to $38.00

EXEL vs. TECH: Which Stock Is the Better Value Option?
EXEL

Zacks

2 months ago

EXEL vs. TECH: Which Stock Is the Better Value Option?

What Makes Exelixis (EXEL) an Investment Bet?
EXEL

Insider Monkey

2 months ago

What Makes Exelixis (EXEL) an Investment Bet?

4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility
EXEL

Zacks

2 months ago

4 PEG-Based Value Stocks to Neutralize Trump 2.0-Led Market Volatility

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
EXEL

Zacks

2 months ago

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today?
EXEL

Simply Wall St.

2 months ago

Should You Be Adding Exelixis (NASDAQ:EXEL) To Your Watchlist Today?

EXEL

MT Newswires

2 months ago

William O'Neil Initiates Exelixis at Buy

EXEL

MT Newswires

2 months ago

Oppenheimer Adjusts Price Target on Exelixis to $41 From $38, Maintains Outperform Rating

BeiGene Stock Meets 80-Plus RS Rating Benchmark
EXEL

Investor's Business Daily

2 months ago

BeiGene Stock Meets 80-Plus RS Rating Benchmark

EXEL

MT Newswires

2 months ago

Truist Raises Price Target on Exelixis to $42 From $38, Maintains Buy Rating

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines
EXEL

Zacks

2 months ago

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and Blueprint Medicines

EXEL

Argus Research

2 months ago

EXEL: Raising target price to $37.00

BridgeBio Pharma Stock Earns 87 RS Rating
EXEL

Investor's Business Daily

2 months ago

BridgeBio Pharma Stock Earns 87 RS Rating

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
EXEL

Zacks

2 months ago

Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again

5 Biotech Stocks Worth Adding to Your Portfolio in 2025
EXEL

Zacks

2 months ago

5 Biotech Stocks Worth Adding to Your Portfolio in 2025

Exelixis Provides Preliminary 2024 Results and Outlook for 2025
EXEL

Zacks

2 months ago

Exelixis Provides Preliminary 2024 Results and Outlook for 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
EXEL

Zacks

2 months ago

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
EXEL

Business Wire

2 months ago

Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
EXEL

Zacks

3 months ago

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

EXEL

MT Newswires

3 months ago

Exelixis Says FDA No Longer Discussing Application for Cabozantinib at Committee Meeting

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
EXEL

Business Wire

3 months ago

Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
EXEL

Business Wire

3 months ago

Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
EXEL

Zacks

3 months ago

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

Exelixis price target raised to $38 from $34 at RBC Capital
EXEL

TipRanks

3 months ago

Exelixis price target raised to $38 from $34 at RBC Capital

High Growth Tech Stocks to Watch in December 2024
EXEL

Simply Wall St.

3 months ago

High Growth Tech Stocks to Watch in December 2024

EXEL

MT Newswires

3 months ago

RBC Capital Adjusts Price Target on Exelixis to $38 From $34, Keeps Outperform Rating

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
EXEL

Zacks

3 months ago

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?
EXEL

Zacks

3 months ago

EXEL vs. INCY: Which Stock Should Value Investors Buy Now?

EXEL

Argus Research

3 months ago

EXEL: Lowering target price to $35.00

Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?
EXEL

Insider Monkey

3 months ago

Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?

EXEL

MT Newswires

3 months ago

Exelixis Shares Decline After BMO Capital Downgrade

EXEL

MT Newswires

3 months ago

BMO Capital Downgrades Exelixis to Market Perform From Outperform, Raises Price Target to $40 From $36

Share on Social Networks: